Marker Therapeutics Stock News

Wall Street brokerages forecast that Marker Therapeutics, Inc. (NASDAQ:MRKR) will report ($0.12) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Marker Therapeutics earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). Marker Therapeutics reported earnings of ($0.18) per share during the same quarter []

Marker Therapeutics Inc. (NASDAQ:MRKR) shares, rose in value on Friday, 11/26/21, with the stock price down by 0.00% to the previous days close as strong demand from buyers drove the stock to $1.23. Actively observing the price movement in the last trading, the stock closed the session at $1.23, falling within a range of $1.20 Is Marker Therapeutics Inc. (NASDAQ) Bullish Or Bearish In 2021? Read More »

Marker Therapeutics Inc. (NASDAQ:MRKR) price on Friday, November 19, rose 3.17% above its previous days close as an upside momentum from buyers pushed the stocks value to $1.30. A look at the stocks price movement, the close in the last trading session was $1.26, moving within a range at $1.28 and $1.40. The beta value Marker Therapeutics Inc. (NASDAQ:MRKR) Stock Could Be Worth Considering Read More »

Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock analysts at Oppenheimer boosted their FY2021 earnings per share estimates for Marker Therapeutics in a research report issued to clients and investors on Wednesday, November 10th. Oppenheimer analyst M. Biegler now anticipates that the company will earn ($0.52) per share for the year, up from their previous estimate of []

Equities research analysts expect Marker Therapeutics, Inc. (NASDAQ:MRKR) to post ($0.12) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Marker Therapeutics earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). Marker Therapeutics posted earnings per share of ($0.18) in the same quarter []

Marker Therapeutics Inc (NASDAQ: MRKR) received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT). The CPRI

The shares of Marker Therapeutics, Inc. (Nasdaq: MRKR) increased by over 15% pre-market. This is why it happened.

HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi

HOUSTON, Aug. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie

HOUSTON, July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi

HOUSTON, July 6, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks

Top penny stocks to buy today? Check these 3 out for your watchlist The post Top Penny Stocks to Buy Today?

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q1 2021 Results - Earnings Call Transcript